Assembly BiosciencesASMB
ASMB
About: Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Employees: 73
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 2 (+1) [Q1 2025]
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
6% more funds holding
Funds holding: 35 [Q4 2024] → 37 (+2) [Q1 2025]
7.75% less ownership
Funds ownership: 50.09% [Q4 2024] → 42.34% (-7.75%) [Q1 2025]
40% less capital invested
Capital invested by funds: $50.3M [Q4 2024] → $30.4M (-$19.9M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$31
84%
upside
Avg. target
$31
84%
upside
High target
$31
84%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Vamil Divan | 84%upside $31 | Buy Initiated | 25 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that Jason Okazaki, chief executive officer and president, and Anuj Gaggar, MD, PhD, chief medical officer, will present in a fireside chat during the Jefferies 2025 Global Healthcare Conference at 8:45 a.m. Eastern Time on June 4, 2025. A live webcast will be available on the Events and Presentations section of Assembly Bio's website and a replay will be accessible following the event. To register for the live webcast and replay, please visit: https://investor.assemblybio.com/events-presentations.
Negative
Zacks Investment Research
1 month ago
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates
– Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 –
Neutral
GlobeNewsWire
1 month ago
New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection markers by ABI-4334, currently in Phase 1b with data anticipated in the first half of 2025 – SOUTH SAN FRANCISCO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced new preclinical and in vitro data for two therapeutic candidates featured in poster presentations, including one late-breaker, at the European Association for the Study of the Liver (EASL) Congress, taking place May 7-10, 2025, in Amsterdam, the Netherlands.
Positive
Zacks Investment Research
1 month ago
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
Positive
Zacks Investment Research
2 months ago
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Zacks Investment Research
2 months ago
Assembly Biosciences (ASMB) Upgraded to Buy: What Does It Mean for the Stock?
Assembly Biosciences (ASMB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline –
Neutral
GlobeNewsWire
3 months ago
Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
– Phase 1a study will evaluate single and multiple ascending doses of ABI-6250 in healthy participants with data expected in Q3 2025 – – Biomarker of ABI-6250 target engagement, serum bile acids, will be assessed in addition to safety and pharmacokinetic measures – SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced that the first participant has been dosed in the Phase 1a trial of ABI-6250, the company's orally bioavailable, small molecule hepatitis delta virus (HDV) entry inhibitor candidate.
Charts implemented using Lightweight Charts™